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RESUMO 
O Incremental Shuttle Walking Test (ISWT) tem sido sugerido como uma boa opção para 
avaliar a aptidão cardiorrespiratória na população saudável. Já se sabe que nos homens o 
ISWT é um teste máximo, porém em mulheres ainda existe essa lacuna. Deste modo, este 
estudo teve como objetivo comparar o ISWT com o teste de exercício cardiopulmonar (TECP) 
e desenvolver uma equação de predição do consumo pico de oxigênio (VO2 pico) em 
mulheres saudáveis. Métodos: No primeiro estágio, o VO2 pico, o quociente respiratório pico 
(R pico), a frequência cardíaca máxima (FC máx) e a porcentagem da FC máx predita (% da 
FC máx prevista) foram avaliados no TECP e ISWT. No segundo estágio, foi elaborada uma 
equação (n = 54) para predizer o VO2 pico. No terceiro, a validação desta equação foi 
realizada por outras 20 participantes. Resultados: Não houve diferenças significativas entre o 
ISWT e TECP para os valores de VO2 pico, FC máx e % da FC máx prevista (P> 0,05), mas a 
medida de R pico foi significativamente maior no ISWT (1,22±0,13 no ISWT vs. 1,18±0,1 no 
TECP; P = 0,022). Além disso, houve uma correlação positiva moderada entre os testes para 
as variáveis VO2 pico (r = 0,51; P = 0,0007), FC máx (r = 0,65; P <0,0001) e R pico (r = 0,55; 
P = 0,0002) e a análise de Bland-Altman demonstrou concordância VO2 pico (bias = -0,14). A 
distância percorrida no ISWT e a idade explicaram 36,3% (R quadrado ajustado = 0,363) da 
variância do VO2 pico. A equação foi: VO2 pico (previsto) = 19,793 + (0,02 x distância 
percorrida) - (0,236 x idade). Não houve diferença estatisticamente significativa entre o VO2 
pico medido diretamente com o estimado pela equação elaborada e a análise de Bland-Altman 
mostrou concordância entre as medidas, com um bias de 1,5 ml / kg / min. Conclusão: O 
ISWT é um teste máximo, mostrando resultados semelhantes aos do TECP e a equação 
prevista é válida e aplicável para avaliação do VO2 pico em mulheres jovens saudáveis. 
Palavras-chave: Incremental Shuttle Walking Test, VO2 pico, mulheres. 
 
 ABSTRACT 
The Incremental Shuttle Walking Test (ISWT), have been suggested as a good option for 
evaluating cardiorespiratory fitness in the healthy population. It is already known that in men 
the ISWT is a maximum test, but in women there is still this gap. Thus, this study aimed to 
compare the ISWT with the cardiopulmonary exercise testing (CEPT) and to develop an 
equation for peak oxygen uptake (VO2 peak) prediction in healthy women. Methods: In the 
first stage, the VO2 peak, respiratory exchange ratio (R peak), heart rate max (HR max) and 
percentage of predicted HR max (% predicted HR max) were evaluated in CEPT and ISWT. 
In the second stage, an equation was elaborated (n = 54) to predict the VO2 peak. In the third, 
the validation of this equation was performed by another 20 participants. Results: There were 
no significant differences between the ISWT and CEPT for VO2 peak, HR max and % 
predicted HR max values (P>0.05), except for R peak measure that was 1.22(0.13) in ISWT 
vs. 1.18(0.1) in CEPT (P=0.022). Therefore, both tests showed a moderate positive correlation 
for VO2 peak (r=0.51; P=0.0007), HR max (r=0.65; P<0.0001) and R peak (r=0.55;  
P=0.0002) and the Bland-Altman analysis demonstrated agreement for VO2 peak (bias = - 
0.14). The distance walked on ISWT and age explained 36.3% (Adjusted R Square = 0.363) 
of the variance in VO2 peak. The equation was VO2 peak (predicted) = 19.793 + (0.02 x 
distance walked) - (0.236 x age).There was no statistically significant difference between VO2 
peak measured directly with that estimated by the elaborated equation and the Bland-Altman 
analysis showed an agreement with a bias of 1.5 ml/kg/min. 
Conclusion: ISWT is a maximal showing similar results as the CEPT, and the predicted 
equation is valid and applicable for evaluation of VO2 peak in young healthy women. 
Keywords: Incremental Shuttle Walking Test, VO2 peak, women. 
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1 INTRODUÇÃO 
 
A aptidão cardiorrespiratória (ACR) pode ser definida como a capacidade de 
executar um exercício de intensidade moderada a alta, de natureza dinâmica, com participação 
de grandes grupos musculares por períodos de tempo prolongados. É um importante 
componente da aptidão física relacionada à saúde, que reflete as capacidades funcionais dos 
sistemas respiratório, cardiovascular e musculoesquelético (ACSM, 2014). 
O padrão ouro para avaliação da ACR é a obtenção do consumo máximo de 
oxigênio (VO2 máx) (ATS, 2003) que reflete a máxima capacidade em absorver, transportar e 
consumir o oxigênio (WASSERMAN, 2012). O VO2 máx é representado por um platô no 
gráfico de VO2 versus trabalho; entretanto, em testes clínicos, um platô pode não ser 
encontrado antes que outros sintomas (como frequência cardíaca ou volume sistólico) levem à 
interrupção do exercício (ATS, 2003). Por isso, de maneira prática, o VO2 máx é considerado 
sinônimo do VO2 pico, ou seja, é equivalente ao maior valor de VO2 obtido no pico do 
esforço (ATS, 2003; HERDY & CAIXETA, 2016). 
Os principais determinantes do VO2 pico são os fatores genéticos, a quantidade de 
massa muscular, a idade, o sexo e o peso corporal, além de poder ser afetado pelo treinamento 
(ATS, 2003). O mesmo pode ser avaliado através da medida direta dos gases exalados ou por 
equações de predição pré-estabelecidas. 
A mensuração direta do VO2 pico envolve laboratórios especializados com 
equipamentos de alto custo e profissionais especializados (teste de esforço cardiopulmonar- 
TECP), o que nem sempre está disponível na prática clínica (ACSM, 2003). Diante disso, 
testes de campo são cada vez mais utilizados para avaliação da ACR, como o Incremental 
Shuttle Walking Test (ISWT). 
O ISWT foi desenvolvido por Singh et al. em 1992 para avaliar a ACR de 
portadores de doença pulmonar obstrutiva crônica. Trata-se de um teste simples no qual o 
indivíduo deve caminhar/correr em terreno plano uma distância conhecida de 10 metros, ao 
redor de uma marcação de dois cones. Originalmente o teste é composto por 12 estágios de 1 
minuto, sendo que o ritmo da passada é ditado por sinais sonoros que vão se tornando mais 
próximos a cada estágio, levando o voluntário a caminhar em uma velocidade cada vez maior 
para alcançar o próximo cone antes ou junto do próximo sinal, impondo um esforço 
progressivo (SINGH et al., 1992). 
Ressalta-se que a avaliação da ACR tem sido frequentemente realizada tanto na 
prática clínica quanto em investigações científicas, com o intuito de fornecer parâmetros para 
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a prescrição e elaboração de programas de exercícios (PALANGE et al., 2007; ATS, 2006). 
Nesse contexto, o ISWT pode ser uma ferramenta simples e barata para a avaliação da ACR 
em diferentes populações. 
A característica incremental do ISWT explica as fortes correlações encontradas 
entre esse teste e o TECP em pacientes com doenças cardiopulmonares (SINGH et al., 1994; 
MORALES et al., 2000; ONORATI et al., 2003;) e indivíduos saudáveis (DOURADO et al., 
2011; NEVES et al., 2015). Além disso, alguns estudos demonstraram que o ISWT é um teste 
máximo para crianças e idosos (DOURADO et al., 2013; LANZA et al., 2015; PINHO et al., 
2015; VARDHAN et al. 2017). 
Recentemente, nosso grupo de pesquisa demonstrou que em homens jovens saudáveis 
o ISWT foi capaz de promover respostas cardiorrespiratórias máximas. Ainda, foi 
desenvolvida uma equação de predição do VO2 pico que demonstrou viabilidade para sua 
avaliação, com base em variáveis obtidas durante o ISWT (NEVES et al., 2015). Porém, uma 
limitação desse estudo foi não incluir mulheres na amostra. 
Considerando que os valores de VO2 para mulheres representam cerca de 70% da 
média dos valores para homens (NUNES et al., 2005), a investigação do comportamento do 
VO2 durante o ISWT na população feminina é válida e necessária. Os poucos estudos 
publicados avaliaram apenas mulheres obesas (PEIXOTO-SOUZA et al., 2015; 
JÜRGENSEN et al., 2016), permanecendo uma lacuna na literatura sobre o ISWT em 
mulheres saudáveis. 
Diante disso, o objetivo deste estudo foi avaliar a ACR de mulheres jovens 
saudáveis durante o TECP e o ISWT através da medida direta dos gases exalados, a fim de 
classificar a intensidade do ISWT e elaborar uma equação de predição para o VO2 pico para 
essa população. 
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1 Abstract 
2 Introduction: The Incremental Shuttle Walking Test (ISWT), have been suggested as a good 
 
3 option for evaluating cardiorespiratory fitness in the healthy population. It is already known 
 
4 that in men the ISWT is a maximum test, but in women there is still this gap. Thus, this study 
 
5 aimed to compare the ISWT with the cardiopulmonary exercise testing (CEPT) and to 
 
6 develop an equation for peak oxygen uptake (VO2 peak) prediction in healthy women. 
 
7 Methods: In the first stage, the VO2 peak, respiratory exchange ratio (R peak), heart rate max 
 
8 (HR max) and percentage of predicted HR max (% predicted HR max) were evaluated in 
 
9 CEPT and ISWT. In the second stage, an equation was elaborated (n = 54) to predict the VO2 
 
10 peak. In the third, the validation of this equation was performed by another 20 participants. 
 
11 Results: There were no significant differences between the ISWT and CEPT for VO2 peak, 
 
12 HR max and % predicted HR max values (P>0.05), except for R peak measure that was 
 
13 1.22(0.13)  in  ISWT  vs.  1.18(0.1)  in  CEPT  (P=0.022).  Therefore,  both  tests  showed  a 
 
14 moderate positive correlation for VO2 peak (r=0.51; P=0.0007), HR max (r=0.65; P<0.0001) 
 
15 and R peak (r=0.55; P=0.0002) and the Bland-Altman analysis demonstrated agreement for 
 
16 VO2 peak (bias = -0.14). The distance walked on ISWT and age explained 36.3% (R² 
 
17 Adjusted= 0.363) of the variance in VO2 peak. The equation was VO2 peak (predicted) = 
 
18 19.793  +  (0.02  x  distance  walked)  -  (0.236  x  age).There  was  no  statistically significant 
 
19 difference  between  VO2   peak  measured  directly  with   that   estimated  by  the  elaborated 
 
20 equation and the Bland-Altman analysis showed an agreement with a bias of 1.5 ml/kg/min. 
 
21 Conclusion: ISWT is a maximal test showing similar results as the CEPT, and the predicted 
 
22 equation is valid and applicable for evaluation of VO2 peak in young healthy women. 
 
23 Keywords: Incremental Shuttle Walking Test, VO2 peak, women. 
19 
 
24 Introduction 
 
 
25 Cardiorespiratory fitness (CRF) is defined as the ability to sustain dynamic exercise by 
 
26 large muscle groups over time at moderate to high intensity levels [1]. Furthermore, CRF 
 
27 have  been  used  to  measure  exercise  capacity  and  provide  information  about  physical 
 
28 limitation,  morbidity  prognosis,  and  responsiveness  to  treatment  [2].  The  current  gold 
 
29 standard for the evaluation of CRF is the direct measurement of maximal oxygen uptake 
 
30 (VO2max) which represents the maximal achievable level of  oxidative metabolism  involving 
 
31 large muscle groups [3]. However, in clinical testing situations, the exercise usually is limited 
 
32 by symptoms before the individual achieve the VO2max. Consequently, VO2 peak is often 
 
33 used as an estimate for VO2max and they are used interchangeably [3]. 
 
 
34 The laboratory assessment of CRF through maximal tests on treadmills or cycle 
 
35 ergometers   (cardiopulmonary  exercise  testing-CEPT)  has   a   high   cost   [4]   and require 
 
36 specialized professionals and equipments that is not always available [5]. Thus, field tests 
 
37 were developed and have been increasingly used in clinical practice, such as the Six-minute 
 
38 walk test and the Incremental Shuttle Walking Test (ISWT). ISWT was created by Singh et al. 
 
39 [6] to assess the CRF of patients with chronic pulmonary obstructive disease (COPD) and 
 
40 later used in other conditions or healthy subjects [7, 8, 9, 10, 11]. 
 
41 Several studies had already shown strong correlations between the performance on 
 
42 CEPT and ISWT [5, 12, 13, 14]. Some studies have showed that the ISWT is a maximal test 
 
43 in the pediatric and elderly population [15, 16, 17, 18], however the intensity of ISWT was 
 
44 often  indirectly  assessed  by  predictive  equations  [15,  16,  17].  Hence,  our  study  group 
 
45 compared cardiorespiratory responses between ISWT and CEPT in healthy young adult men 
 
46 [14]  and adolescent  boys  (data not  published),  where  the results  showed moderate to high 
 
47 significant correlation and agreement, concluding that the ISWT is a maximal test in these 
20 
 
48 subjects. In addition, a VO2 peak prediction equation based on ISWT variables was developed 
 
49 and it demonstrated feasibility and validity [14]. However, this study did not include women 
 
50 in the assessments, remaining a gap in the literature about the ISWT in healthy women. 
 
 
51 In this paper, we evaluate the CRF in healthy young women by comparing and 
 
52 correlating VO2 peak, respiratory quotient peak (R peak), maximum heart rate (HR max) and 
 
53 percentage of predicted maximum heart rate (% predicted HR max), between ISWT with 
 
54 CEPT through direct analysis of the exhaled gases, aiming to classify the ISWT intensity and 
 
55 to elaborate a predictive equation to estimate the VO2 peak in young adult women population. 
 
56 Materials and methods 
 
 
57 Design 
 
 
58 This was a cross-sectional study divided into three stages: (1) To compare the CEPT 
 
59 and the ISWT, evaluate the correlation and agreement between the variables VO2 peak, R 
 
60 peak, HR max and % predicted HR max, as well as determine the ISWT intensity in the 
 
61 female population; (2) To elaborate an equation to predict the VO2 peak; and (3) validate the 
 
62 equation. The sample size was calculated using the statistical program G.Power 3.1 and was 
 
63 based on the relationship between the number of variables to be included in the multiple 
 
64 regression analysis and the minimum number of observations required, considering an effect 
 
65 size of 0.68 and power  of 0.99, it was  necessary 54  volunteers  in order  to develop  a  linear 
 
66 model containing up to 4 variables [14]. To validate the equation, another 20 volunteers were 
 
67 required [14]. 
 
68 Subjects 
21 
 
69 Women between 18 and 45 years of age were recruited by convenience from 
 
70 Diamantina city,  Minas  Gerais  state,  Brazil.  The inclusion  criteria were:  self-report  of no 
 
71 acute or chronic diseases; eutrophic according to the body mass index (BMI between 18.5 and 
 
72 24.9 kg/m²); no smoker; sedentary (not performing physical activity for 30 minutes or more at 
 
73 least three times a week) [19]. The participants were excluded from the study if did not reach 
 
74 the maximal test values on the treadmill (% predicted HR max higher than 90%) and those 
 
75 who failed to understand the tests. This study was approved by the Ethics and Research 
 
76 Committee of Universidade Federal dos Vales do Jequitinhonha e Mucuri, Brazil (protocol 
 
77 1.184.419/2015) and conducted in accordance with the Resolution Nº 466/12 of the National 
 
78 Health Council and the Declaration of Helsink. The participants were informed about the 
 
79 procedures  and  potential  risks  associated  with  the  study  and  all  gave  written  informed 
 
80 consent. 
 
81 Assessment of cardiorespiratory fitness 
 
 
82 To evaluate the cardiorespiratory fitness, all participants were instructed to avoid 
 
83 physical activity and intake caffeine and alcohol in the 24 h prior to the test, to get at least 8 
 
84 hours of sleep  the night  before,  to eat  a light meal and to ingest  500 ml  of water two hours 
 
85 before  the  tests  [19].  During  all  tests  performed,  the  exhaled  gases  were  collected  and 
 
86 assessed by a portable telemetric gas analysis system (K4b2, Cosmed, Rome, Italy). Among 
 
87 other variables, VO2, R  and HR breath-by-breath were monitored. The data were tabulated 
 
88 and was defined as VO2 peak and R peak the highest value of these measures at peak effort 
 
89 [20]. Predicted HR max was calculated by the equation HR max = 220 – age [21]. 
 
90 The first phase of the study was performed on three consecutive days. On the first day, 
 
91 the anthropometric variables  weight,  height  and  BMI,  were measured  and a familiarization 
 
92 was   performed.   On   subsequent   days,   the   CEPT   or   the   ISWT   was   performed   by 
 
93 randomization. 
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94 The ISWT was performed in a 10-m course identified by two cones placed 0.5 m from 
 
95 each  end  point, with  an  initial  speed  of  0.5  m/s,  increasing  0.17  m/s  every  minute. The 
 
96 protocol used was composed of 15 stages of 1 min, to prevent the ceiling effect [10, 22] and 
 
97 the walking speed was dictated by a sound [6]. The test was interrupted if the volunteer did 
 
98 not reach the cone once, at the request of the volunteer or for some other reported symptom 
 
99 (dyspnea, dizziness, vertigo, and angina). The CEPT protocol was based on the progression of 
 
100 the  ISWT, with  the same initial  speed  and the  same speed increase  every minute,   without 
 
101 changing the  incline  of  the  treadmill.  The  criteria  for interrupting the  CEPT  was systolic 
 
102 blood pressure (SBP) greater than 210 mm Hg; diastolic blood pressure greater than 120 mm 
 
103 Hg; sustained decrease in SBP; angina; dyspnea; cyanosis; nausea; dizziness; or by 
 
104 volunteer's request [19]. 
 
105 In the second and third stage, the participants performed two ISWT with an interval of 
 
106 30 minutes between then [23] and the results of the test with the longest walking distance 
 
107 were used for the statistical analysis. To validate the equation, a different group of women 
 
108 was selected according to the same inclusion criteria of the study. The VO2 peak obtained by 
 
109 the gas analyzer was compared with the VO2 peak predicted by the elaborated equation. 
 
110 Statistical analysis 
 
 
111 Statistical analysis was performed with the Statistical Package for Social Sciences 
 
112 programs version 22.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5.0 (Inc., USA). 
 
113 Data were presented as mean (standard deviation). In the first stage the normality of the data 
 
114 was calculated by Shapiro-Wilk test. As the data presented normal distribution, the 
 
115 comparison between the means of the physiological variables evaluated (VO2 peak, R peak, 
 
116 HR max and % predicted HR max) were performed using Paired T-test. The correlation 
 
117 analysis of the variables collected was performed by Pearson`s correlation. The agreement of 
23 
 
118 the variables collected was performed by the Bland-Altman analysis. In the second stage, the 
 
119 Kolmogorov-Smirnov  test  was  used,  and  the  analysis   of  multiple  linear  regression  was 
 
120 performed with the variables age, weight, height and distance walked defined a priori to 
 
121 elaborate  the  VO2 peak  prediction  equation. For  the validation of the equation, the Shapiro- 
 
122 Wilk test was performed and then the paired T-test to compare the mean values of the VO2 
 
123 peak  values  obtained  by  the  equation  with  those  obtained  by  the  analyzer  of  gases.  In 
 
124 addition, the comparison 
 
125 between the women of first and third stages were realized using the Independent test t or 
 
126 Mann-Whitney  test,  according  of  normality  of  data.  The  level  of  statistical  significance 
 
127 adopted was P <0.05. 
 
128 Results 
 
 
129 First stage: Comparison between CEPT and ISWT 
 
 
130 The general characteristics of the participants of first and second stage and their 
 
131 performance on ISWT are showed in table 1. 
 
 
132 Table 1. General characteristics of participants study. 
 
 
Variable N=54 
Age (years) 26.41± 5.6 (24.89-27.92) 
Weight (kg) 56.56 ± 9.1 (54.08-59.05) 
Height (m) 
 
BMI (kg/m²) 
1.63 ± 0.1 (1.608-1.641) 
 
21.86 ± 1.8 (21.38-22.33) 
 
 
24 
 
 
Distance walked (m) 
 
Walking speed (m/s) 
821.10 ± 118.9 (788.7-853.6) 
 
2.06 ± 0.2 (2.013-2.104) 
 
 
133 The data is presented as mean ± SD (95% CI). BMI = body mass index. 
 
 
134 Forty volunteers performed both ISWT and CEPT and their cardiorespiratory 
 
135 responses are presented in table 2. There was no statistically significant difference for any of 
 
136 the  variables,  except  for  the  R  peak,  which  was  higher  in  the  ISWT.  According  to the 
 
137 percentage of predicted HR max (above 90%) and R peak (> 1.1), the ISWT could be 
 
138 considered a test of maximum intensity [14, 24, 25]. Blood pressure and heart rate were 
 
139 monitored during all tests and there were no intercurrences. 
 
 
140 Table 2. Comparison between the cardiorespiratory variables obtained in the ISWT and 
 
141 in the CEPT. 
 
 
Outcome Groups Comparison between 
interventions 
 ISWT 
(n = 40) 
CEPT 
(n = 40) 
P-value 
VO2 peak (mL/kg/min) 30.20(4.78) 30.35(4.81) 0.842 
R peak 1.22(0.13) 1.18(0.1) 0.022* 
HR max (bpm) 
 
Predicted HR max (%) 
187.6(9.26) 
 
97.25(4.51) 
186.7(9.63) 
 
96.77(4.69) 
0.460 
 
0.463 
 
142 The data is presented as mean (SD). *P<0.05. ISWT = Incremental Shuttle Walking Test; CEPT= 
143 cardiopulmonary exercise test; VO2 = oxygen uptake; R = respiratory exchange ratio; HR = heart rate; Paired-t 
144 test. 
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145 Significant correlations were found for the variables VO2 peak, HR max and R peak 
146 (Fig 1). The Bland-Altman analysis also demonstrated agreement between the VO2 peak in the 
147 ISWT and in the CEPT (Fig 2). 
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150 Fig 1. Correlation between (A) VO2 peak, (B) HR max and (C) R peak in the ISWT and 
151 the CEPT. ISWT = Incremental Shuttle Walking Test; CEPT= cardiopulmonary exercise 
152 test; VO2 = oxygen uptake; HR max = maximum heart rate; R = respiratory exchange ratio. 
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153  
154 Fig 2. Bland-Altman agreement of VO2 peak in the ISWT and the CEPT. ISWT = 
155 Incremental Shuttle Walking Test; CEPT= cardiopulmonary exercise test; VO2 = oxygen 
156 uptake. 
157 Second stage: Reference equation for VO2 peak 
 
158 The univariate analysis was performed with the variables age, weight, height and 
 
159 distance walked (N=54). A model of stepwise linear multiple regressions showed distance 
 
160 walked on ISWT and age explained 36.3% (Adjusted R Square = 0.363) of the variance in 
 
161 VO2 peak. The reference equation for the VO2 peak in the ISWT was: 
 
162 VO2 peak (predicted) = 19.793 + (0.02 x distance walked) - (0.236 x age) 
 
163 Third stage: Validation of the reference equation 
 
 
164 The characteristics of the volunteers who participated in the equation validation are 
 
165 present in table 3. 
 
 
166 Table 3. General characteristics of the study participants. 
 
 
Variable N=20 
Age (years) 25.85 ± 5.6 (23,24-28,46) 
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                                                      +1.96 SD 
10.93 
1.5 
24 28 32 36 40 
                                                      -1.96 SD 
-7.92 
 
Mean (Direct VO2 peak- VO2 equation) 
 
Weight (kg) 55.84 ± 5.7 (53.16-58.51) 
Height (m) 
BMI (kg/m²) 
Distance walked (m) 
 
Walking speed (m/s) 
1.62 ± 0.04 (1.594-1.638) 
 
21.34 ± 1.5 (20.61-22.07) 
 
865 ± 100.2 (818.1-911.9) 
 
2.11 ± 0.14 (2.049-2.181) 
 
 
167 The data is presented as mean ± SD (95% CI). BMI = body mass index. 
 
 
168 There was no statistically significant difference between the participants of equation 
 
169 elaboration and validation for age, weight, height, BMI, Distance walked and Walking speed 
 
170 (P>0.05; data not show). 
 
 
171 When the reference equation was applied in this group, there was no statistically 
 
172 significant difference of the VO2 peak obtained by the use of the gold standard method in 
 
173 comparison to that obtained by the equation [32.50 (5.6) mL/kg/min and 30.99 (2.6) mL/ kg/ 
 
174 min, respectively; p = 0.178)]. It was possible to verify the agreement between these measures 
 
175 by the Bland-Altman method, in which a bias of 1.5 mL/kg/min was observed, representing a 
 
176 difference of 3.6% between the ways of measuring VO2 peak (Fig 3). 
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178 Fig 3. Bland-Altman agreement of VO2 peak in the validation of the reference equation. 
 
179 ISWT = Incremental Shuttle Walking Test; CEPT= cardiopulmonary exercise test; VO2 = 
 
180 oxygen uptake. 
 
181 Discussion 
 
 
182 In the present study it was observed that the direct VO2 peak measurement was 
 
183 concordant between the CEPT and the ISWT and that ISWT was a maximum test in the 
 
184 young healthy women population. Considering that the direct analysis of VO2 is not feasible 
 
185 for clinical practice, an equation was elaborated and validated to estimate this measure. The 
 
186 distance walked on ISWT and age were the variables that composed the equation. 
 
187 Furthermore, there was agreement between VO2 peak measured directly and that estimated by 
 
188 the elaborated equation, indicating its validity and applicability in this population. 
 
 
189 In the last years the ISWT has been applying in the healthy population [10, 11, 18, 26]. 
 
190 However, as far as we know, this is the first study that a comparison between CEPT and 
 
191 ISWT was performed in healthy young women. Initial investigations were carried out in 
 
192 patients with COPD, cystic fibrosis and chronic heart failure, showing strong and significant 
 
193 correlations for VO2 peak of CEPT and ISWT [7, 9, 12]. 
 
 
194 In a study recently published by our research group, male healthy adults showed HR 
 
195 max, VO2 peak and R peak values with strong and significant correlations and agreement 
 
196 between the ISWT and the CEPT, with ISWT being a maximal test for this population [14]. 
 
197 Considering that the maximum VO2 values for women are about 70% of the average values 
 
198 for men [27] and that is not known whether ISTW is a maximum test for healthy young 
 
199 women, we initially investigated the intensity of ISTW. 
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200 Since the values of HR max above 90% of predicted and R peak > 1.1 [14, 24, 25], we 
 
201 establish that this is a maximum test for this population, and similar VO2 peak results were 
 
202 found between CEPT and ISWT. Further tests carried out with patients with cardiopulmonary 
 
203 diseases concurred with our findings [6, 12, 28, 29]. However, data on the validity of the 
 
204 ISWT to evaluate VO2 peak in healthy individuals are scarce in the literature [18]. Gonçalves 
 
205 et. al [30], studying subjects of both sexs, different age (≥ 18 years old), who presented 
 
206 comorbidities   such   as   arterial   hypertension,   peripheral   vascular   disease,   arthritis and 
 
207 cardiopathies, also concluded that ISWT above 12 levels requires maximum effort in these 
 
208 individuals. 
 
209 As the direct analysis of the exhaled gases has a high cost, the use of prediction 
 
210 equations becomes more applicable due to the feasibility and low cost. Considering our results 
 
211 that ISTW is a maximum test to healthy women, its usefulness is reinforced as a simple way 
 
212 of measuring CRF. In this context, an equation was then elaborated for the prediction of VO2 
 
213 peak in ISTW. 
 
214 In our study, age and distance walked accounted for more than 30% of VO2 peak 
 
215 variance. In the literature it is reported that beyond gender, other factors that influence VO2 
 
216 peak as  genetic  factors,  age, weight,  and training  [31].  Findings  similar to  our study were 
 
217 found in obese women, where there was a significant correlation between the VO2 peak in the 
 
218 cardiopulmonary exercise test with the ISWT VO2 peak and the ISWT distance [5]. In this 
 
219 same study,  the variables  age  and  distance  walked  by the  ISWT  explained  the predictive 
 
220 model for the VO2 peak. 
 
221 Only two other studies have published a reference equation for VO2 peak using ISWT, 
 
222 highlighting the variables distance and body mass in the prediction [11, 32]. In the study of 
 
223 Dourado et. al [11]  the distance in the ISWT was selected, the maximum walking velocity, 
 
224 and distance in the ISWT × body mass as the only determinants of the peak VO2. This is 
30 
 
225 consistent with the variables selected in our study. However, they did not compare to another 
 
226 cardiopulmonary exercise test, nor did they validate the equation. 
 
227 As age is a determining factor for VO2 peak, it is important to highlight that several 
 
228 studies have used the ISWT in the older population [10, 11, 22, 23, 26] or in children and 
 
229 adolescents [15-17], and some evaluated stratifying age groups [2, 30]. Due to the influence 
 
230 of cardiorespiratory fitness on functional independence, there is great interest in describing 
 
231 age-related changes in maximum oxygen consumption. Evidences support a 10% per decade 
 
232 decline in VO2 max in men and women regardless of activity level [33]. For all the facts 
 
233 reported, it makes sense for age to be a predictor of VO2 peak in the elaborated equation. 
 
234 Our study presents differentials when proposing a prediction equation for VO2 peak, 
 
235 the main variable for evaluation of cardiorespiratory fitness [19, 34], since most of the studies 
 
236 with ISWT focus on the prediction of walking distance [2, 10, 15, 17, 22, 23]. In addition, 
 
237 those who did the VO2 peak prediction equation for women did not validate it [5, 11]. The 
 
238 equation developed in this study was validated in other volunteers and the VO2 peak values 
 
239 obtained by the equation and the values of VO2 peak obtained by the gas analyzer were 
 
240 similar, indicating that the application of the equation is feasible to estimate the VO2 peak of 
 
241 the chosen population. 
 
242 The limitation of the study was the level of physical activity having been self-reported, 
 
243 but this strategy is adopted in scientific studies [35, 36]. 
 
244 Conclusion 
 
 
245 The Incremental Shuttle Walking Test was concordant with the CEPT, requiring 
 
246 maximum effort in young health women. The elaborated equation is valid and applicable, 
 
247 being a simple and inexpensive tool to evaluate the cardiorespiratory fitness in the study 
 
248 population. 
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 Tables are inserted immediately after the first paragraph in which they are 
cited. 
 Supporting information files are uploaded separately. 
 
 
 
Viewing    Figures    and    Supporting    Information     in     the     compiled     submission     PDF  
The compiled submission PDF includes low-resolution preview images of the figures after the 
reference list. The function of these previews is to allow you to download the entire submission as 
quickly as possible. Click the link at the top of each preview page to download a high-resolution 
version of each figure. Links to download Supporting Information files are also available after the 
reference list. 
 
Parts of a Submission 
Title 
Include a full title and a short title for the manuscript. 
 
Title Length Guidelines Examples 
Full 
title 
250 
characters 
Specific, descriptive, concise, 
and comprehensible to readers 
Impact of cigarette smoke exposure on innate 
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  outside the field immunity: A Caenorhabditis elegans model 
 
Solar drinking water disinfection (SODIS) to 
reduce childhood diarrhoea in rural Bolivia: A 
cluster-randomized, controlled trial 
Short 
title 
100 
characters 
State the topic of the study Cigarette smoke exposure and innate immunity 
 
SODIS and childhood diarrhoea 
 
Titles should be written in sentence case (only the first word of the text, proper nouns, and genus 
names are capitalized). Avoid specialist abbreviations if possible. For clinical trials, systematic 
reviews, or meta-analyses, the subtitle should include the study design. 
 
Author list 
 
Author names and affiliations 
 
Enter author names on the title page of the manuscript and in the online submission system. 
On the title page, write author names in the following order: 
 First name (or initials, if used) 
 Middle name (or initials, if used) 
 Last name (surname, family name) 
 
Each author on the list must have an affiliation. The affiliation includes department, university, or 
organizational affiliation and its location, including city, state/province (if applicable), and country. 
Authors have the option to include a current address in addition to the address of their affiliation at the 
time of the study. The current address should be listed in the byline and clearly labeled “current 
address.” At a minimum, the address must include the author’s current institution, city, and country. 
 
If an author has multiple affiliations, enter all affiliations on the title page only. In the submission 
system, enter only the preferred or primary affiliation. Author affiliations will be listed in the typeset 
PDF article in the same order that authors are listed in the submission. 
 
Corresponding author 
 
The submitting author is automatically designated as the corresponding author in the submission 
system. The corresponding author is the primary contact for the journal office and the only author able 
to view or change the manuscript while it is under editorial consideration. 
 
The corresponding author role may be transferred to another coauthor. However, note that transferring 
the corresponding author role also transfers access to the manuscript. (To designate a new 
corresponding author while the manuscript is still under consideration, watch the video  tutorial 
below.) 
 
Only one corresponding author can be designated in the submission system, but this does not restrict 
the number of corresponding authors that may be listed on the article in the event of publication. 
Whoever is designated as a corresponding author on the title page of the manuscript file will be listed 
as such upon publication. Include an email address for each corresponding author listed on the title 
page of the manuscript. 
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Consortia and group authorship 
 
If a manuscript is submitted on behalf of a consortium or group, include the consortium or group name 
in the author list, and provide the full list of consortium or group members in the Acknowledgments 
section. The consortium or group name should be listed in the manuscript file only, and not included  
in the online submission form. Please be aware that as of October 2016, the National Library of 
Medicine’s (NLM) policy has changed and PubMed will only index individuals and the names of 
consortia or group authors listed in the author byline itself. Individual consortium or group author 
members need to be listed in the author byline in order to be indexed, and if included in the byline, 
must qualify for authorship according to our criteria. 
 
Author contributions 
 
Provide at minimum one contribution for each author in the submission system. Use the CRediT 
taxonomy to describe each contribution. Read the policy and the full list of roles. 
 
Contributions will be published with the final article, and they should accurately reflect contributions 
to the work. The submitting author is responsible for completing this information at submission, and 
we expect that all authors will have reviewed, discussed, and agreed to their individual contributions 
ahead of this time. 
 
PLOS ONE will contact all authors by email at submission to ensure that they are aware of the 
submission. 
 
Cover letter 
 
Upload a cover letter as a separate file in the online system. The length limit is 1 page. 
The cover letter should include the following information: 
 Summarize the study’s contribution to the scientific literature 
 Relate the study to previously published work 
 Specify the type of article (for example, research article, systematic review, meta-analysis, 
clinical trial) 
 Describe any prior interactions with PLOS regarding the submitted manuscript 
 Suggest appropriate Academic Editors to handle your manuscript (see the full list of Academic 
Editors) 
 List any opposed reviewers 
Title page 
The title, authors, and affiliations should all be included on a title page as the first page of the 
manuscript file. 
 
Abstract 
 
The Abstract comes after the title page in the manuscript file. The abstract text is also entered in a 
separate field in the submission system. 
 
The Abstract should: 
 
 Describe the main objective(s) of the study 
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 Explain how the study was done, including any model organisms used, without 
methodological detail 
 Summarize the most important results and their significance 
 Not exceed 300 words 
Abstracts should not include: 
 Citations 
 Abbreviations, if possible 
Introduction 
The introduction should: 
 
 Provide background that puts the manuscript into context and allows readers outside the field 
to understand the purpose and significance of the study 
 Define the problem addressed and why it is important 
 Include a brief review of the key literature 
 Note any relevant controversies or disagreements in the field 
 Conclude with a brief statement of the overall aim of the work and a comment about whether 
that aim was achieved 
 
Materials and Methods 
 
The Materials and Methods section should provide enough detail to allow suitably skilled investigators 
to fully replicate your study. Specific information and/or protocols for new methods should be 
included in detail. If materials, methods, and protocols are well established, authors may cite articles 
where those protocols are described in detail, but the submission should include sufficient information 
to be understood independent of these references. 
 
Protocol documents for clinical trials, observational studies, and other non-laboratory investigations 
may be uploaded as supporting information. Read the supporting information guidelines for formatting 
instructions. We recommend depositing laboratory protocols at protocols.io. Read detailed instructions 
for depositing and sharing your laboratory protocols. 
 
Human or animal subjects and/or tissue or field sampling 
 
Methods sections describing research using human or animal subjects and/or tissue or field sampling 
must include required ethics statements. See the reporting guidelines for human research, clinical 
trials, animal research, and observational and field studies for more information. 
 
Data 
 
PLOS journals require authors to make all data underlying the findings described in their manuscript 
fully available without restriction, with rare exception. 
 
Large data sets, including raw data, may be deposited in an appropriate public repository. See our list 
of recommended repositories. 
 
For smaller data sets and certain data types, authors may provide their data within supporting 
information files accompanying the manuscript. Authors should take care to maximize the 
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accessibility and reusability of the data by selecting a file format from which data can be efficiently 
extracted (for example, spreadsheets or flat files should be provided rather than PDFs when providing 
tabulated data). 
 
For more information on how best to provide data, read our policy on data availability. PLOS does not 
accept references to “data not shown.” 
 
Cell lines 
 
Methods sections describing research using cell lines must state the origin of the cell lines used. See 
the reporting guidelines for cell line research for more information. 
 
Laboratory Protocols 
 
To enhance the reproducibility of your results, we recommend and encourage you to deposit 
laboratory protocols in protocols.io, where protocols can be assigned their own persistent digital object 
identifiers (DOIs). 
 
To include a link to a protocol in your article: 
 
1. Describe your step-by-step protocol on protocols.io 
2. Select Get DOI to issue your protocol a persistent digital object identifier (DOI) 
3. Include the DOI link in the Methods section of your manuscript using the following format 
provided by protocols.io: http://dx.doi.org/10.17504/protocols.io.[PROTOCOL DOI] 
 
At this stage, your protocol is only visible to those with the link. This allows editors and reviewers to 
consult your protocol when evaluating the manuscript. You can make your protocols public at any 
time by selecting Publish on the protocols.io site. Any referenced protocol(s) will automatically be 
made public when your article is published. 
 
New taxon names 
 
Methods sections of manuscripts adding new taxon names to the literature must follow the reporting 
guidelines below for a new zoological taxon, botanical taxon, or fungal taxon. 
 
Results, Discussion, Conclusions 
 
These sections may all be separate, or may be combined to create a mixed Results/Discussion section 
(commonly labeled “Results and Discussion”) or a mixed Discussion/Conclusions section (commonly 
labeled “Discussion”). These sections may be further divided into subsections, each with a concise 
subheading, as appropriate. These sections have no word limit, but the language should be clear and 
concise. 
 
Together, these sections should describe the results of the experiments, the interpretation of these 
results, and the conclusions that can be drawn. 
 
Authors should explain how the results relate to the hypothesis presented as the basis of the study and 
provide a succinct explanation of the implications of the findings, particularly in relation to previous 
related studies and potential future directions for research. 
 
PLOS ONE editorial decisions do not rely on perceived significance or impact, so authors should 
avoid overstating their conclusions. See the PLOS ONE Criteria for Publication for more information. 
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URL. Read the Preprint Policy. 
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Do 
not 
cite 
the 
foll 
owi 
ng 
sour 
ces 
in 
the 
reference list: 
 
 Unavailable and unpublished work, including manuscripts that have been submitted but not 
yet accepted (e.g., “unpublished work,” “data not shown”). Instead, include those data as 
supplementary material or deposit the data in a publicly available database. 
 Personal communications (these should be supported by a letter from the relevant authors but 
not included in the reference list) 
 
References are listed at the end of the manuscript and numbered in the order that they appear in the 
text. In the text, cite the reference number in square brackets (e.g., “We used the techniques developed 
by our colleagues [19] to analyze the data”). PLOS uses the numbered citation (citation-sequence) 
method and first six authors, et al. 
 
Do not include citations in abstracts or author summaries. 
 
Make sure the parts of the manuscript are in the correct order before ordering the citations. 
Formatting references 
PLOS uses the reference style outlined by the International Committee of Medical Journal Editors 
(ICMJE), also referred to as the “Vancouver” style. Example formats are listed below. Additional 
examples are in the ICMJE sample references. 
 
Journal name abbreviations should be those found in the National Center for Biotechnology 
Information (NCBI) databases. 
 
Supporting Information 
 
Authors can submit essential supporting files and multimedia files along with their manuscripts. All 
supporting information will be subject to peer review. All file types can be submitted, but files must be 
smaller than 10 MB in size. 
 
Authors may use almost any description as the item name for a supporting information file as long as  
it contains an “S” and number. For example, “S1 Appendix” and “S2 Appendix,” “S1 Table” and “S2 
Table,” and so forth. 
 
Supporting information files are published exactly as provided, and are not copyedited. 
Supporting information captions 
List supporting information captions at the end of the manuscript file. Do not submit captions in a 
separate file. 
written works) http://blogs.plos.org/plos/2010/09/announcing-plos-blogs/. 
Masters' theses or 
doctoral 
dissertations 
Wells A. Exploring the development of the independent, electronic, scholarly 
journal. M.Sc. Thesis, The University of Sheffield. 1999. Available from: 
http://cumincad.scix.net/cgi-bin/works/Show?2e09 
Databases and 
repositories 
(Figshare, arXiv) 
Roberts SB. QPX Genome Browser Feature Tracks; 2013 [cited 2013 Oct 5]. 
Database: figshare [Internet]. Available from: 
http://figshare.com/articles/QPX_Genome_Browser_Feature_Tracks/701214 
Multimedia 
(videos, movies, or 
TV shows) 
Hitchcock A, producer and director. Rear Window [Film]; 1954. Los Angeles: 
MGM. 
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The file number and name are required in a caption, and we highly recommend including a one-line 
title as well. You may also include a legend in your caption, but it is not required. 
 
In-text citations 
 
We recommend that you cite supporting information in the manuscript text, but this is not a 
requirement. If you cite supporting information in the text, citations do not need to be in numerical 
order. 
 
Figures and Tables 
Figures 
Do not include figures in the main manuscript file. Each figure must be prepared and submitted as an 
individual file. 
 
Cite figures in ascending numeric order upon first appearance in the manuscript file. 
Figure captions 
Figure captions must be inserted in the text of the manuscript, immediately following the paragraph in 
which the figure is first cited (read order). Do not include captions as part of the figure files 
themselves or submit them in a separate document. 
 
At a minimum, include the following in your figure captions: 
 
 A figure label with Arabic numerals, and “Figure” abbreviated to “Fig” (e.g. Fig 1, Fig 2,    
Fig 3, etc). Match the label of your figure with the name of the file uploaded at submission 
(e.g. a figure citation of “Fig 1” must refer to a figure file named “Fig1.tif”). 
 A concise, descriptive title 
 
The caption may also include a legend as needed. 
Tables 
Cite tables in ascending numeric order upon first appearance in the manuscript file. 
 
Place each table in your manuscript file directly after the paragraph in which it is first cited (read 
order). Do not submit your tables in separate files. 
 
Tables require a label (e.g., “Table 1”) and brief descriptive title to be placed above the table. Place 
legends, footnotes, and other text below the table. 
 
Data reporting 
 
All data and related metadata underlying the findings reported in a submitted manuscript should be 
deposited in an appropriate public repository, unless already provided as part of the submitted article. 
 
Repositories may be either subject-specific (where these exist) and accept specific types of structured 
data, or generalist repositories that accept multiple data types. We recommend that authors select 
repositories appropriate to their field. Repositories may be subject-specific (e.g., GenBank for 
sequences and PDB for structures), general, or institutional, as long as DOIs or accession numbers are 
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provided and the data are at least as open as CC BY. Authors are encouraged to select repositories that 
meet accepted criteria as trustworthy digital repositories, such as criteria of the Centre for Research 
Libraries or Data Seal of Approval. Large, international databases are more likely to persist than small, 
local ones. 
 
To support data sharing and author compliance of the PLOS data policy, we have integrated our 
submission process with a select set of data repositories. The list is neither representative nor 
exhaustive of the suitable repositories available to authors. Current repository integration partners 
include Dryad and FlowRepository. Please contact data@plos.org to make recommendations for 
further partnerships. 
 
Instructions for PLOS submissions with data deposited in an integration partner repository: 
 
 Deposit data in the integrated repository of choice. 
 Once deposition is final and complete, the repository will provide you with a dataset DOI 
(provisional) and private URL for reviewers to gain access to the data. 
 Enter the given data DOI into the full Data Availability Statement, which is requested in the 
Additional Information section of the PLOS submission form. Then provide the URL 
passcode in the Attach Files section. 
 
If you have any questions, please email us. 
Accession numbers 
All appropriate data sets, images, and information should be deposited in an appropriate public 
repository. See our list of recommended repositories. 
 
Accession numbers (and version numbers, if appropriate) should be provided in the Data Availability 
Statement. Accession numbers or a citation to the DOI should also be provided when the data set is 
mentioned within the manuscript. 
 
In some cases authors may not be able to obtain accession numbers of DOIs until the manuscript is 
accepted; in these cases, the authors must provide these numbers at acceptance. In all other cases, 
these numbers must be provided at submission. 
 
Identifiers 
 
As much as possible, please provide accession numbers or identifiers for all entities such as genes, 
proteins, mutants, diseases, etc., for which there is an entry in a public database, for example: 
 
 Ensembl 
 Entrez Gene 
 FlyBase 
 InterPro 
 Mouse Genome Database (MGD) 
 Online Mendelian Inheritance in Man (OMIM) 
 PubChem 
 
Identifiers should be provided in parentheses after the entity on first use. 
Striking image 
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You can choose to upload a “Striking Image” that we may use to represent your article online in places 
like the journal homepage or in search results. 
 
The striking image must be derived from a figure or supporting information file from the submission, 
i.e., a cropped portion of an image or the entire image. Striking images should ideally be high 
resolution, eye-catching, single panel images, and should ideally avoid containing added details such 
as text, scale bars, and arrows. 
 
If no striking image is uploaded, we will designate a figure from the submission as the striking image. 
Additional Information Requested at Submission 
Funding Statement 
 
This information should not be in your manuscript file; you will provide it via our submission system. 
 
This information will be published with the final manuscript, if accepted, so please make sure that this 
is accurate and as detailed as possible. You should not include this information in your manuscript file, 
but it is important to gather it prior to submission, because your financial disclosure statement cannot 
be changed after initial submission. 
 
Your statement should include relevant grant numbers and the URL of any funder's web site. Please 
also state whether any individuals employed or contracted by the funders (other than the named 
authors) played any role in: study design, data collection and analysis, decision to publish, or 
preparation of the manuscript. If so, please name the individual and describe their role. 
 
Competing Interests 
 
This information should not be in your manuscript file; you will provide it via our submission system. 
 
All potential competing interests must be declared in full. If the submission is related to any patents, 
patent applications, or products in development or for market, these details, including patent numbers 
and titles, must be disclosed in full. 
 
Manuscripts disputing published work 
 
For manuscripts disputing previously published work, it is PLOS ONE policy to invite a signed review 
by the disputed author during the peer review process. This procedure is aimed at ensuring a thorough, 
transparent, and productive review process. 
 
If the disputed author chooses to submit a review, it must be returned in a timely fashion and contain a 
full declaration of all competing interests. The Academic Editor will consider any such reviews in 
light of the competing interest. 
 
Authors submitting manuscripts disputing previous work should explain the relationship between the 
manuscripts in their cover letter, and will be required to confirm that they accept the conditions of this 
review policy before the manuscript is considered further. 
 
Related manuscripts 
 
Upon submission, authors must confirm that the manuscript, or any related manuscript, is not currently 
under consideration or accepted elsewhere. If related work has been submitted to PLOS ONE or 
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elsewhere, authors must include a copy with the submitted article. Reviewers will be asked to 
comment on the overlap between related submissions. 
 
We strongly discourage the unnecessary division of related work into separate manuscripts, and we 
will not consider manuscripts that are divided into “parts.” Each submission to PLOS ONE must be 
written as an independent unit and should not rely on any work that has not already been accepted for 
publication. If related manuscripts are submitted to PLOS ONE, the authors may be advised to 
combine them into a single manuscript at the editor's discretion. 
 
PLOS does support authors who wish to share their work early and receive feedback before formal 
peer review. Deposition of manuscripts with preprint servers does not impact consideration of the 
manuscript at any PLOS journal. 
 
Authors choosing bioRxiv may  now  concurrently  submit  directly  to  select  PLOS  journals  
through bioRxiv’s direct transfer to journal service. 
 
Guidelines for Specific Study Types 
Human subjects research. 
Manuscripts should conform to the following reporting guidelines: 
 
 Studies of diagnostic accuracy: STARD 
 Observational studies: STROBE 
 Microarray experiments: MIAME 
 Other types of health-related research: Consult the EQUATOR web site for appropriate 
reporting guidelines 
 
Methods sections of papers on research using human subjects or samples must include ethics 
statements that specify: 
 
 The name of the approving institutional review board or equivalent committee(s). If approval 
was not obtained, the authors must provide a detailed statement explaining why it was not 
needed 
 Whether informed consent was written or oral. If informed consent was oral, it must be stated 
in the manuscript: 
o Why written consent could not be obtained 
o That the Institutional Review Board (IRB) approved use of oral consent 
o How oral consent was documented 
 
For studies involving humans categorized by race/ethnicity, age, disease/disabilities, religion, 
sex/gender, sexual orientation, or other socially constructed groupings, authors should: 
 
 Explicitly describe their methods of categorizing human populations 
 Define categories in as much detail as the study protocol allows 
 Justify their choices of definitions and categories, including for example whether any rules of 
human categorization were required by their funding agency 
 Explain whether (and if so, how) they controlled for confounding variables such as 
socioeconomic status, nutrition, environmental exposures, or similar factors in their analysis 
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In addition, outmoded terms and potentially stigmatizing labels should be changed to more current, 
acceptable terminology. Examples: “Caucasian” should be changed to “white” or “of [Western] 
European descent” (as appropriate); “cancer victims” should be changed to “patients with cancer.” 
 
For papers that include identifying, or potentially identifying,  information, authors  must download 
the Consent Form for Publication in a PLOS Journal, which the individual, parent, or guardian must 
sign once they have read the paper and been informed about the terms of PLOS open-access license. 
The signed consent form should not be submitted with the manuscript, but authors should securely file 
it in the individual's case notes and the methods section of the manuscript should explicitly state that 
consent authorization for publication is on file, using wording like: 
 
The individual in this manuscript has given written informed consent (as outlined in PLOS consent 
form) to publish these case details. 
 
For  more   information   about PLOS   ONE policies   regarding   human   subjects   research,   see   
the Publication Criteria and Editorial Policies. 
 
Clinical trials 
 
Clinical trials are subject to all policies regarding human research. PLOS ONE follows the World 
Health Organization's (WHO) definition of a clinical trial: 
 
A clinical trial is any research study that prospectively assigns human participants or groups of 
humans to one or more health-related interventions to evaluate the effects on health outcomes [...] 
Interventions include but are not restricted to drugs, cells and other biological products, surgical 
procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, 
preventive care, etc. 
 
All clinical  trials  must  be  registered  in  one  of  the  publicly-accessible  registries  approved  by  
the WHO or ICMJE (International Committee of Medical Journal Editors). Authors must provide the 
trial registration number. Prior disclosure of results on a clinical trial registry site will not affect 
consideration for publication. We reserve the right to inform authors' institutions or ethics committees, 
and to reject the manuscript, if we become aware of unregistered trials. 
 
PLOS ONE supports prospective trial registration (i.e. before participant recruitment has begun) as 
recommended by the ICMJE's clinical trial registration policy. Where trials were not publicly 
registered before participant recruitment began, authors must: 
 
 Register all related clinical trials and confirm they have done so in the Methods section 
 Explain in the Methods the reason for failing to register before participant recruitment 
 
Clinical trials must be reported according to the relevant reporting guidelines, i.e. CONSORT for 
randomized controlled trials, TREND for non-randomized trials, and other specialized guidelines as 
appropriate. The intervention should be described according to the requirements of the TIDieR 
checklist and guide. Submissions must also include the study protocol as supporting information, 
which will be published with the manuscript if accepted. 
 
Authors of manuscripts describing the results of clinical trials must adhere to the CONSORT reporting 
guidelines appropriate to their trial design, available on the CONSORT Statement web site. Before the 
paper can enter peer review, authors must: 
 
 Provide the registry name and number in the methods section of the manuscript 
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 Provide a copy of the trial  protocol  as  approved  by  the  ethics  committee  and  a  
completed CONSORT checklist as supporting information (which will be published alongside 
the paper, if accepted). This should be named S1 CONSORT Checklist. 
 Include the CONSORT flow diagram as the manuscript's “Fig 1” 
 
Any deviation from the trial protocol must be explained in the paper. Authors must explicitly discuss 
informed consent in their paper, and we reserve the right to ask for a copy of the patient consent form. 
 
The methods section must include the name of the registry, the registry number, and the URL of your 
trial in the registry database for each location in which the trial is registered. 
 
Animal research 
 
Manuscripts reporting animal research must state in the Methods section: 
 
 The full name of the relevant ethics committee that approved the work, and the associated 
permit number(s). 
 Where ethical approval is not required, the manuscript should include a clear statement of this 
and the reason why. Provide any relevant regulations under which the study is exempt from 
the requirement for approval. 
 Relevant details of steps taken to ameliorate animal suffering. 
 
Authors should always state the organism(s) studied in the Abstract. Where the study may be confused 
as pertaining to clinical research, authors should also state the animal model in the title. 
 
To maximize reproducibility and  potential  for  re-use  of  data,  we  encourage  authors  to  follow  
the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines for all submissions 
describing laboratory-based animal research and to upload a completed ARRIVE Guidelines  
Checklist to be published as supporting information. 
 
Non-human primates 
 
Manuscripts describing research involving non-human primates must report details of husbandry and 
animal welfare in accordance with the recommendations of the Weatherall report, The use of non- 
human primates in research (PDF), including: 
 
 Information about housing, feeding, and environmental enrichment. 
 Steps taken to minimize suffering, including use of anesthesia and method of sacrifice, if 
appropriate. 
 
Random source animals 
 
Manuscripts describing studies that use random source (e.g. Class B dealer-sourced in the USA), 
shelter, or stray animals will be subject to additional scrutiny and may be rejected if sufficient ethical 
and scientific justification for the study design is lacking. 
 
Unacceptable euthanasia methods and anesthetic agents 
 
Manuscripts reporting use of a euthanasia method(s) classified as unacceptable by the American 
Veterinary Medical Association or use of an anesthesia method(s) that is widely prohibited (e.g., 
chloral hydrate, ether, chloroform) must include at the time of initial submission, scientific 
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justification for use in the specific study design, as well as confirmation of approval for specific use 
from their animal research ethics committee. These manuscripts may be subject to additional ethics 
considerations prior to publication. 
 
Humane endpoints 
 
Manuscripts reporting studies in which death of a regulated animal (vertebrate, cephalopod) is a likely 
outcome or a planned experimental endpoint, must comprehensively report details of study design, 
rationale for the approach, and methodology, including consideration of humane endpoints. This 
applies to research that involves, for instance, assessment of survival, toxicity, longevity, terminal 
disease, or high rates of incidental mortality. 
 
Full details of humane endpoints use must be reported for a study to be reproducible and for the results 
to be accurately interpreted. 
 
For studies in which death of an animal is an outcome or a planned experimental endpoint, authors 
should include the following information in the Methods section of the manuscript: 
 
 The specific criteria (i.e. humane endpoints) used to determine when animals should be 
euthanized. 
 The duration of the experiment. 
 The numbers of animals used, euthanized, and found dead (if any); the cause of death for all 
animals. 
 How frequently animal health and behavior were monitored. 
 All animal welfare considerations taken, including efforts to minimize suffering and distress, 
use of analgesics or anaesthetics, or special housing conditions. 
 
If humane endpoints were not used, the manuscript should report: 
 
 A scientific justification for the study design, including the reasons why humane endpoints 
could not be used, and discussion of alternatives that were considered. 
 Whether the institutional animal ethics committee specifically reviewed and approved the 
anticipated mortality in the study design. 
 
Observational and field studies 
 
Methods sections for submissions reporting on any type of field study must include ethics statements 
that specify: 
 
 Permits and approvals obtained for the work, including the full name of the authority that 
approved the study; if none were required, authors should explain why 
 Whether the land accessed is privately owned or protected 
 Whether any protected species were sampled 
 Full details of animal husbandry, experimentation, and care/welfare, where relevant 
Paleontology and archaeology research 
Manuscripts reporting paleontology and archaeology research must include descriptions of methods 
and specimens in sufficient detail to allow the work to be reproduced. Data sets supporting statistical 
and phylogenetic analyses should be provided, preferably in a format that allows easy re-use. Read the 
policy. 
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Specimen numbers and complete repository information, including museum name and geographic 
location, are required for publication. Locality information should be provided in the manuscript as 
legally allowable, or a statement should be included giving details of the availability of such 
information to qualified researchers. 
 
If permits were required for any aspect of the work, details should be given of all permits that were 
obtained, including the full name of the issuing authority. This should be accompanied by the 
following statement: 
 
All necessary permits were obtained for the described study, which complied with all relevant 
regulations. 
 
If no permits were required, please include the following statement: 
 
No permits were required for the described study, which complied with all relevant regulations. 
 
Systematic reviews and meta-analyses 
 
A systematic review paper, as defined by The Cochrane Collaboration, is a review of a clearly 
formulated question that uses explicit, systematic methods to identify, select, and critically appraise 
relevant research, and to collect and analyze data from the studies that are included in the review. 
These reviews differ substantially from narrative-based reviews or synthesis articles. Statistical 
methods (meta-analysis) may or may not be used to analyze and summarize the results of the included 
studies. 
 
Reports of systematic reviews and meta-analyses must include a completed PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) checklist and flow diagram to 
accompany the main text. Blank templates are available here: 
 
 Checklist: PDF or Word document 
 Flow diagram: PDF or Word document 
 
Authors must also state in their “Methods” section whether a protocol exists for their systematic 
review, and if so, provide a copy of the protocol as supporting information and provide the registry 
number in the abstract. 
 
If your article is a systematic review or a meta-analysis you should: 
 
 State this in your cover letter 
 Select “Research Article” as your article type when submitting 
 Include the PRISMA flow diagram as Fig 1 (required where applicable) 
 Include the PRISMA checklist as supporting information 
Meta-analysis of genetic association studies 
Manuscripts reporting a meta-analysis of genetic association studies must report results of value to the 
field and should be reported according to the guidelines presented in Systematic Reviews of Genetic 
Association Studies by Sagoo et al. 
 
On submission, authors will be asked to justify the rationale for the meta-analysis and how it 
contributes to the base of scientific knowledge in the light of  previously published results. Authors 
will also be asked to complete a checklist (DOCX) outlining information about the justification for the 
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study and the methodology employed. Meta-analyses that replicate published studies will be rejected if 
the authors do not provide adequate justification. 
 
Personal data from third-party sources 
 
For all studies using personal data from internet-based and other third-party sources (e.g., social 
media, blogs, other internet sources, mobile phone companies), data must be collected and used 
according to company/website Terms and Conditions, with appropriate permissions. All data sources 
must be acknowledged clearly in the Materials and Methods section. 
 
In the Ethics Statement, authors should declare any potential risks to individuals or individual privacy, 
or affirm that in their assessment, the study posed no such risks. In addition, the following Ethics and 
Data Protection requirements must be met. 
 
For interventional studies, which impact participants’ experiences or data, the study design must have 
been prospectively approved by an Ethics Committee, and informed consent is required. The Ethics 
Committee may waive the requirement for approval and/or consent. 
 
For observational studies in which personal experiences and accounts are not manipulated, 
consultation with an Ethics or Data Protection Committee is recommended. Additional requirements 
apply in the following circumstances: 
 
 If information used could threaten personal privacy or damage the reputation of individuals 
whose data are used, an Ethics Committee should be consulted and informed consent obtained 
or specifically addressed. 
 If authors accessed any personal identifying information, an Ethics or Data Protection 
Committee should oversee data anonymization. If data were anonymized and/or aggregated 
before access and analysis, informed consent is generally not required. 
 
Cell lines 
 
Authors reporting research using cell lines should state when and where they obtained the cells, giving 
the date and the name of the researcher, cell line repository, or commercial source (company) who 
provided the cells, as appropriate. 
 
Authors must also include the following information for each cell line: 
 
For de novo (new) cell lines, including those given to the researchers as a gift, authors must follow our 
policies for human subjects research or animal research, as appropriate. The ethics statement must 
include: 
 
 Details of institutional review board or ethics committee approval; AND 
 For human cells, confirmation of written informed consent from the donor, guardian, or next 
of kin 
 
For established cell lines, the Methods section should include: 
 
 A reference to the published article that first described the cell line; AND/OR 
 The cell line repository or company the cell line was obtained from, the catalogue number, and 
whether the cell line was obtained directly from the repository/company or from another 
laboratory 
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Authors should check established cell lines using the ICLAC Database of Cross-contaminated or 
Misidentified Cell Lines to confirm they are not misidentified or contaminated. Cell line  
authentication is recommended – e.g., by karyotyping, isozyme analysis, or short tandem repeats 
(STR) analysis – and may be required during peer review or after publication. 
 
Blots and gels 
 
Manuscripts reporting results from blots (including Western blots) and electrophoretic gels should 
follow these guidelines: 
 
 In accordance with our policy on image manipulation, the image should not be adjusted in any 
way that could affect the scientific information displayed, e.g. by modifying the background  
or contrast. 
 All blots and gels that support results reported in the manuscript should be provided. 
 Original uncropped and unadjusted blots and gels, including molecular size markers, should 
be provided in either the figures or the supplementary files. 
 Lanes should not be overcropped around the bands; the image should show most or all of the 
blot or gel. Any non-specific bands should be shown and an explanation of their nature should 
be given. 
 The image should include all relevant controls, and controls should be run on the same blot or 
gel as the samples. 
 A figure panel should not include composite images of bands originating from different blots 
or gels. If the figure shows non-adjacent bands from the same blot or gel, this should be 
clearly denoted by vertical black lines and the figure legend should provide details of how the 
figure was made. 
 
Antibodies 
 
Manuscripts reporting experiments using antibodies should include the following information: 
 
 The name of each antibody, a description of whether it is monoclonal or polyclonal, and the 
host species. 
 The commercial supplier or source laboratory. 
 The catalogue or clone number and, if known, the batch number. 
 The antigen(s) used to raise the antibody. 
 For established antibodies, a stable public identifier from the Antibody Registry. 
 
The manuscript should also report the following experimental details: 
 
 The final antibody concentration or dilution. 
 A reference to the validation study if the antibody was previously validated. If not, provide 
details of how the authors validated the antibody for the applications and species used. 
 
Small and macromolecule crystal data 
 
Manuscripts reporting new and unpublished three-dimensional structures must include sufficient 
supporting data and detailed descriptions of the methodologies used to allow the reproduction and 
validation of the structures. All novel structures must have been deposited in a community endorsed 
database prior to submission (please see our list of recommended repositories). 
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Small molecule single crystal data 
 
Authors reporting X-Ray crystallographic structures of small organic, metal-organic, and inorganic 
molecules must deposit their data with the Cambridge Crystallographic Data Centre (CCDC), the 
Inorganic Crystal Structure Database (ICSD), or similar community databases providing a recognized 
validation functionality. Authors are also required to include the relevant structure reference numbers 
within the main text (e.g. the CCDC ID number), as well as the crystallographic information files (.cif 
format) as Supplementary Information, along with the checkCIF validation reports that can be 
obtained via the International Union of Crystallography (IUCr). 
 
Macromolecular structures 
 
Authors reporting novel macromolecular structures must have deposited their data prior to submission 
with the Worldwide Protein Data Bank (wwPDB), the Biological Magnetic Resonance Data Bank 
(BMRB), the Electron Microscopy Data Bank (EMDB), or other community databases providing a 
recognized validation functionality. Authors must include the structure reference numbers within the 
main text and submit as Supplementary Information the official validation reports from these 
databases. 
 
Methods, software, databases, and tools 
 
PLOS ONE will consider submissions that present new methods, software, or databases as the primary 
focus of the manuscript if they meet the following criteria: 
 
Software submissions 
 
Manuscripts whose primary purpose is the description of new software must provide full details of the 
algorithms designed. Describe any dependencies on commercial products or operating system. Include 
details of the supplied test data and explain how to install and run the software. A brief description of 
enhancements made in the major releases of the software may also be given. Authors should provide a 
direct link to the deposited software from within the paper. 
 
Database submissions 
 
For descriptions of databases, provide details about how the data were curated, as well as plans for 
long-term database maintenance, growth, and stability. Authors should provide a direct link to the 
database hosting site from within the paper. 
 
New taxon names 
Zoological names 
When publishing papers that describe a new zoological taxon name, PLOS aims to comply with the 
requirements of the International Commission on Zoological Nomenclature (ICZN). Effective 1 
January 2012, the ICZN considers an online-only publication to be legitimate if it meets the criteria of 
archiving and is registered in ZooBank, the ICZN's official registry. 
 
For proper registration of a new zoological taxon, we require two specific statements to be included in 
your manuscript. 
 
In the Results section, the globally unique identifier (GUID), currently in the form of a Life Science 
Identifier (LSID), should be listed under the new species name, for example: 
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Anochetus boltoni Fisher sp. nov. urn:lsid:zoobank.org:act:B6C072CF-1CA6-40C7-8396- 
534E91EF7FBB 
 
You will need to contact Zoobank to obtain a GUID (LSID). Please do this as early as possible to 
avoid delay of publication upon acceptance of your manuscript. It is your responsibility to provide us 
with this information so we can include it in the final published paper. 
 
Please also insert the following text into the Methods section, in a sub-section to be called 
“Nomenclatural Acts”: 
 
All PLOS articles are deposited in PubMed Central and LOCKSS. If your institute, or those of your 
co-authors, has its own repository, we recommend that you also deposit the published online article 
there and include the name in your article. 
 
Botanical names 
 
When publishing papers that describe a new botanical taxon, PLOS aims to comply with the 
requirements of the International Code of Nomenclature for algae, fungi, and plants (ICN). The 
following guidelines for publication in an online-only journal have been agreed such that any scientific 
botanical name published by us is considered effectively published under the rules of the Code. Please 
note that these guidelines differ from those for zoological nomenclature, and apply only to seed plants, 
ferns, and lycophytes. 
 
Effective January 2012, the description or diagnosis of a new taxon can be in either Latin or English. 
This does not affect the requirements for scientific names, which are still to be Latin. 
 
Also effective January 2012, the electronic PDF represents a published work according to the ICN for 
algae, fungi, and plants. Therefore the new names contained in the electronic publication of PLOS 
article are effectively published under that Code from the electronic edition alone, so there is no longer 
any need to provide printed copies. 
 
Additional information describing recent changes to the Code can be found here. 
 
For proper registration of the new taxon, we require two specific statements to be included in your 
manuscript. 
 
In the Results section, the globally unique identifier (GUID), currently in the form of a Life Science 
Identifier (LSID), should be listed under the new species name, for example: 
 
Solanum aspersum S.Knapp, sp. nov. [urn:lsid:ipni.org:names:77103633-1] Type: Colombia. 
Putumayo: vertiente oriental de la Cordillera, entre Sachamates y San Francisco de Sibundoy, 1600- 
1750 m, 30 Dec 1940, J. Cuatrecasas 11471 (holotype, COL; isotypes, F [F-1335119], US [US- 
1799731]). 
 
Journal staff will contact IPNI to obtain the GUID (LSID) after your manuscript is accepted for 
publication, and this information will then be added to the manuscript during the production phase 
 
In the Methods section, include a sub-section called “Nomenclature” using the following wording: 
 
All PLOS articles are deposited in PubMed Central and LOCKSS. If your institute, or those of your 
co-authors, has its own repository, we recommend that you also deposit the published online article 
there and include the name in your article. 
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Fungal names 
 
When publishing papers that describe a new botanical taxon, PLOS aims to comply with the 
requirements of the International Code of Nomenclature for algae, fungi, and plants (ICN). The 
following guidelines for publication in an online-only journal have been agreed such that any scientific 
botanical name published by us is considered effectively published under the rules of the Code. Please 
note that these guidelines differ from those for zoological nomenclature. 
 
Effective January 2012, the description or diagnosis of a new taxon can be in either Latin or English. 
This does not affect the requirements for scientific names, which are still to be Latin. 
 
Also effective January 2012, the electronic PDF represents a published work according to the ICN for 
algae, fungi, and plants. Therefore the new names contained in the electronic publication of PLOS 
article are effectively published under that Code from the electronic edition alone, so there is no longer 
any need to provide printed copies. 
 
Additional information describing recent changes to the Code can be found here. 
 
For proper registration of the new taxon, we require two specific statements to be included in your 
manuscript. 
 
In the Results section, the globally unique identifier (GUID), currently in the form of a Life Science 
Identifier (LSID), should be listed under the new species name, for example: 
 
Hymenogaster huthii. Stielow et al. 2010, sp. nov. [urn:lsid:indexfungorum.org:names:518624] 
 
You will need to contact either Mycobank or Index Fungorum to obtain the GUID (LSID). Please do 
this as early as possible to avoid delay of publication upon acceptance of your manuscript. It is your 
responsibility to provide us with this information so we can include it in the final published paper. 
Effective January 2013, all papers describing new fungal species must reference the identifier issued 
by a recognized repository in the protologue in order to be considered effectively published. 
 
In the Methods section, include a sub-section called “Nomenclature” using the following wording (this 
example is for taxon names submitted to MycoBank; please substitute appropriately if you have 
submitted to Index Fungorum): 
 
All PLOS articles are deposited in PubMed Central and LOCKSS. If your institute, or those of your 
co-authors, has its own repository, we recommend that you also deposit the published online article 
there and include the name in your article. 
 
Qualitative research 
 
Qualitative research studies use non-quantitative methods to address a defined research question that 
may not be accessible by quantitative methods, such as people's interpretations, experiences, and 
perspectives. The analysis methods are explicit, systematic, and reproducible, but the results do not 
involve numerical values or use statistics. Examples of qualitative data sources include, but are not 
limited to, interviews, text documents, audio/video recordings, and free-form answers to 
questionnaires and surveys. 
 
Qualitative research studies should be reported in accordance to the Consolidated criteria for reporting 
qualitative research (COREQ) checklist. Further reporting guidelines can be found in the Equator 
Network's Guidelines for reporting qualitative research. 
